Sponsor: MUSC
Sponsor Study ID: 103973
Study Title: Phase II Study Evaluating NALIRIFOX versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients with Locally Advanced and Metastatic Pancreatic Adenocarcinoma
CTO #: 103973
NCT Number: NCT07076212
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Pancreas
Study Objectives: Compare the anti-tumor activity of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC. To assess the safety of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC. To evaluate the anti-tumor activity of the NALIRIFOX and mGAP regimens in patients with locally advanced, unresectable, and metastatic PDAC.